Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$8.31 USD
+0.32 (4.01%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $8.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IRWD 8.31 +0.32(4.01%)
Will IRWD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet
Other News for IRWD
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
First Week of June 21st Options Trading For Ironwood Pharmaceuticals (IRWD)
Ironwood management to meet with Craig-Hallum
Ironwood management to meet with Craig-Hallum
Piper Sandler Reaffirms Their Buy Rating on Ironwood Pharma (IRWD)